| _J. B. CHEMICALS & PHARMACEUTICALS LIMITED REGO, OFFICE: PHONE c22.2sne 2022 2352 0918 NEELAM CENTRE’ 'B WING, 4TH FLR, Fax 022-2899 0594 2399 9693, Hino CYCLE ROAD, WORK ‘ermal nfeojorot ccm MUMBAI - 400 030. Website wa ep.c0m CoN: Laxsaotara7aPLona360 STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 3009/2015. aun saa —— Se [Translation Gain # (Loss) (5-6) ne ae 050.5 4 3728, 16284 Se a a ee I rece yJ. B. CHEMICALS & PHARMACEUTICALS LIMITED REGO. OFFICE: PHONE: 022.2402 2902 2499 0818 LAM CENTRE 8 WING, 4TH FLA FAX: 022.2496 0538 2590 9688 HIND CYCLE ROAD, WORK ‘mal: info@eol com MUMBAL- 409 030 Website: wm jpep.com CIN LaassonHtia76PLcorese0 IvEsTOR compLans ae 5 Monts ended 3090972015 Pending a he Seiing ofa arer 3 Received deg the quarter . Dosed of ring he cuter ° Remaining vreotved a the ee ofthe quarter ° noes Tr ere inerearesls have been evewedby aust commie a approve by he oad of deco als ecg ton November 4, 201. 2 The stato ars have cari cut Ia rvew fhe above thei ess lr be quarter ended on Seonbe a oa 3-Theinceas in ter inome represents gon sae redemption cinvestnenis 4 The cempanys engaged ina sngle segment of aity vie Pharmaceveae The stemert asset ndlabtes sof Sepember 30, 2015 4a under, (nats) Puc aT ASAT soroynos | avoarors JEGoTTY AN ARTES Serene ands |. stare capa ei60] 169616 > Reserves and ups 5393499 [Sub Total of shareholders ands 7.09 96722 | —101.60.15 Non-crren abies Long-term sores : 400 >. Deter ax bites Net), ren! 202 Lone tem prvisns s3e1sa] —yam6o sub-Toxa- Norcent abies 3,508.80 3bea2 current abies 2. sror:caembarowings wimss| —1o4rar rade payatie ooi7es| 623076 ether ae abes race! ase o. shorttem srovsions ear] saa7sat sus-Toxat- Current bites Soa7aer| 9840.06 [roraL-equrry aND uaaiumies 70.0] —14aa7603 Js. Fined ase 4916.9| — a5e0409 . Nor-curen nextments ons] nonsr I Long tem oan and avances wea] yaar sub-Tua- Noncurent assets, ear] —searnsr Curent ase Js. caren vestments new] see. > ivertories naw] eer [Trade ecevabes wisn] aes a. cash and ean equvsienis ono 905.52 le sharttem oss and advances sasoso] 9.71832 | omer cure asets [suo-Tout- Curent assets Tareas | aa maae frova.-assers 344,080.63] 149.876 03 ‘The prevous quater sper ures have been reroupedie sated, wherever cesta, For 18, Chemical & Pharmaceuticals ——Spruedy Pace: Mumba — Ted & manogng Director Date: Novenber 4,215, oeJ.B. CHEMICALS & PHARMACEUTICALS LIMITED REGD. OFFICE: PHONE 022.2482 2222/2403 0018 ‘NEELAM CENTRE’, "2 WING, 4TH FLA. Fax 022.249 0538/2499 9633 HIND CYCLE ROAD, WORLL ‘e-mail :infowbept.com uMAl- 400 000. Wobste- www joop.com Ca: L2azaon41976P1.C018580 Press Release BSE Scrip Code: 506943 NSE Symbol: JBCHEPHARM Mumbai, November 4, 2015 Unaudited Financial Results for Q 2- 2015-16 J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its standalone unaudited financial results for the quarter ended on September 30, 2015. The highlights of Y-o-Y results are as under: (Rs. in crores) Particulars __[92-2015-16 | Q2-2014-15 NetSales 280.71 274.86 Other Operating income _ 6.07 5.40 Other Income = 26.52 5.20 | Total Income 31330 | 285.46 EBIDTA 71 54.95 Operating Profit 38.85 39.73 Profit before tax _ ae 62.29 42.68 Profit after tax 7 48.99 31.89 EPS (Rs) FV 2) 7 Z 578 3.76 The net sales for the quarter at Rs, 280.71 crores were marginally higher against net sales in the corresponding quarter in the previous year. The growth in top line was impacted due to overall lower exports. The PBT and PAT for the quarter at Rs. 62.29 crores and Rs. 48.99 crores were 45.93% and 53.62% higher respectively over corresponding quarter in the previous year. The domestic formulations business at sales of Rs. 108.18 crores registered growth of 11.06%, while the focus products group achieved growth of 17%. The focus on cardiovascular products and topical preparations to drive the growth for the division during the year has met with good success. The contrast media products sales in domestic market at sales of Rs. 10.87 crores registered growth of 22.43%. The overall formulations exports at Rs. 133.03 crores registered growth of 3.06% during the quarter. While the exports for Russia-CIS markets at Rs. 16.78 crores grew by 35.14%, the exports to Rest of the world markets at Rs. 88.63 crores were lower due to lower demand and uncertainty in many markets largely due to depreciation of local currency against USS.J. B. CHEMICALS & PHARMACEUTICALS LIMITED REGO. OFFICE: PHONE : 022 2482 2272 2499 0918 NEELAM CENTRE? "8 WING, 4TH FLA Fx 022-2490 0534 / 2493 9653, HIND CYCLE ROAD. WORL. ema: info@jpepleon ‘muMBat - 409.030. Website: wwnibealcom Cin :t2asgonHne7ePLcor93s0 The API sales at Rs, 22.21 crores were lower. The product development income and other sales income during the quarter amounted to Rs. 6.42 crores. Acquisition: With a view to consolidate control and expand business in African continent, the board of directors has today also approved acquisition of 21,94,030 (51%) ordinary shares in Biotech Laboratories (Pty.) Ltd., South Africa (“Biotech”), held by Africa Biopharma Investments (Pty.) Ltd. by a company’s subsidiary, subject to necessary approvals and definitive agreements to be entered into with the seller. The company’s subsidiary J.B, Healhcare Pvt. Ltd. presently holds 21,07,990 (49%) ordinary shares in Biotech, besides 175,591 Non-Redeemable Convertible Preference Shares. Post the proposed acquisition, conversion of preference shares and certain fresh issuance of ordinary shares by Biotech, the shareholding of the company’s subsidiaries in Biotech will increase to over 95%. About JBCPL: JBCPL, one of India’s leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and APIs. JBCPL exports to many countries worldwide with a strong presence in Russia, Ukraine, CIS countries and South Africa. The Company continues to invest in growing its share in the regulated markets in USA, Europe and Australia. JBCPL has a strong R & D and regulatory set-up for development of new drug delivery system and formulations, filing of DMFs and ANDAs. Its State-of-the-Art manufacturing facilities are approved by health authorities of regulated markets. For more information on JBCPL visit our website at www.jbepl.com. For more details, you may contact: M.C. Mehta Company Secretary and Vice President- Compliance J. B. Chemicals & Pharmaceuticals Ltd. 91 22 2482 2311 Forward Looking Statements: This Press Release may contain Forward Looking Statements regarding future events and future performance of .B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ ‘materially from those that may be indicated by such statements.